Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Upgrade Now
NasdaqGM - Delayed Quote USD

Amicus Therapeutics, Inc. (FOLD)

Compare
7.95
-0.21
(-2.57%)
At close: April 1 at 4:00:01 PM EDT
7.99
+0.04
+(0.50%)
Pre-Market: 5:00:58 AM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
528,295
528,295
399,356
329,233
305,514
Cost of Revenue
52,943
52,943
37,326
38,599
34,466
Gross Profit
475,352
475,352
362,030
290,634
271,048
Operating Expense
441,288
441,288
435,524
495,060
470,968
Operating Income
34,064
34,064
-73,494
-204,426
-199,920
Net Non Operating Interest Income Expense
-44,191
-44,191
-43,071
-34,095
-31,962
Other Income Expense
-18,629
-18,629
-33,536
-3,518
-9,672
Pretax Income
-28,756
-28,756
-150,101
-242,039
-241,554
Tax Provision
27,350
27,350
1,483
-5,471
8,906
Net Income Common Stockholders
-56,106
-56,106
-151,584
-236,568
-250,460
Diluted NI Available to Com Stockholders
-56,106
-56,106
-151,584
-236,568
-250,460
Basic EPS
-0.34
-0.18
-0.51
-0.82
-0.92
Diluted EPS
-0.34
-0.18
-0.51
-0.82
-0.92
Basic Average Shares
303,023.25
304,380.50
295,164.52
289,057.20
271,421.99
Diluted Average Shares
303,023.25
304,380.50
295,164.52
289,057.20
271,421.99
Total Operating Income as Reported
24,876
24,876
-77,211
-212,120
-206,434
Total Expenses
494,231
494,231
472,850
533,659
505,434
Net Income from Continuing & Discontinued Operation
-56,106
-56,106
-151,584
-236,568
-250,460
Normalized Income
-48,847.48
-48,847.48
-137,640.50
-229,027.88
-245,517.17
Interest Income
5,407
5,407
7,078
3,024
509
Interest Expense
49,598
49,598
50,149
37,119
32,471
Net Interest Income
-44,191
-44,191
-43,071
-34,095
-31,962
EBIT
20,842
20,842
-99,952
-204,920
-209,083
EBITDA
29,389
29,389
-92,079
-199,578
-202,874
Reconciled Cost of Revenue
52,943
52,943
37,326
38,599
34,466
Reconciled Depreciation
8,547
8,547
7,873
5,342
6,209
Net Income from Continuing Operation Net Minority Interest
-56,106
-56,106
-151,584
-236,568
-250,460
Total Unusual Items Excluding Goodwill
-9,188
-9,188
-17,650
-7,694
-6,771
Total Unusual Items
-9,188
-9,188
-17,650
-7,694
-6,771
Normalized EBITDA
38,577
38,577
-74,429
-191,884
-196,103
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-1,929.48
-1,929.48
-3,706.50
-153.88
-1,828.17
12/31/2021 - 5/31/2007

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

RIGL Rigel Pharmaceuticals, Inc.
17.15
-4.67%
 
RYTM Rhythm Pharmaceuticals, Inc.
50.00
-5.61%
 
INVA Innoviva, Inc.
17.94
-1.05%
 
KPTI Karyopharm Therapeutics Inc.
3.5400
-5.35%
 
BCYC Bicycle Therapeutics plc
7.85
-7.54%
 
ACAD ACADIA Pharmaceuticals Inc.
16.32
-1.75%
 
HALO Halozyme Therapeutics, Inc.
61.87
-3.04%
 
CYTK Cytokinetics, Incorporated
37.50
-6.69%
 
PTCT PTC Therapeutics, Inc.
46.60
-8.56%
 
RARE Ultragenyx Pharmaceutical Inc.
33.84
-6.55%